Concepts (132)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Radiosurgery | 6 | 2017 | 1330 | 0.590 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 5 | 2018 | 2370 | 0.510 |
Why?
|
| Radiometry | 3 | 2009 | 980 | 0.500 |
Why?
|
| Piperidines | 3 | 2022 | 1035 | 0.360 |
Why?
|
| Pyridazines | 2 | 2022 | 293 | 0.320 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 2009 | 209 | 0.310 |
Why?
|
| Algorithms | 2 | 2009 | 3890 | 0.300 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 5 | 2022 | 5319 | 0.250 |
Why?
|
| Radiotherapy Dosage | 7 | 2018 | 3842 | 0.220 |
Why?
|
| Vaping | 1 | 2023 | 33 | 0.220 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2020 | 4757 | 0.210 |
Why?
|
| Electronic Nicotine Delivery Systems | 1 | 2023 | 63 | 0.210 |
Why?
|
| Tobacco Products | 1 | 2023 | 120 | 0.200 |
Why?
|
| Lung Neoplasms | 6 | 2022 | 11538 | 0.190 |
Why?
|
| Radiotherapy, Computer-Assisted | 2 | 2010 | 126 | 0.180 |
Why?
|
| Models, Biological | 1 | 2008 | 3254 | 0.170 |
Why?
|
| Pyrimidines | 2 | 2022 | 3518 | 0.160 |
Why?
|
| Smoking Cessation | 1 | 2023 | 712 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2020 | 419 | 0.150 |
Why?
|
| Norepinephrine | 1 | 2017 | 272 | 0.150 |
Why?
|
| Epinephrine | 1 | 2017 | 255 | 0.140 |
Why?
|
| Carbazoles | 1 | 2016 | 87 | 0.140 |
Why?
|
| Particle Accelerators | 2 | 2010 | 352 | 0.140 |
Why?
|
| Spinal Neoplasms | 2 | 2012 | 631 | 0.140 |
Why?
|
| Brain Neoplasms | 3 | 2022 | 4849 | 0.140 |
Why?
|
| Biophysical Phenomena | 2 | 2010 | 112 | 0.130 |
Why?
|
| Immunotherapy, Adoptive | 2 | 2016 | 1763 | 0.130 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2017 | 323 | 0.130 |
Why?
|
| Radiotherapy, Image-Guided | 1 | 2018 | 304 | 0.130 |
Why?
|
| Lymphocyte Depletion | 1 | 2016 | 264 | 0.130 |
Why?
|
| Phantoms, Imaging | 4 | 2018 | 1271 | 0.130 |
Why?
|
| Watchful Waiting | 1 | 2017 | 289 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2017 | 370 | 0.120 |
Why?
|
| Radiation Dosage | 1 | 2018 | 1014 | 0.110 |
Why?
|
| Cone-Beam Computed Tomography | 2 | 2010 | 202 | 0.100 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2016 | 502 | 0.100 |
Why?
|
| Antigens, CD19 | 1 | 2014 | 577 | 0.100 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2016 | 992 | 0.100 |
Why?
|
| Models, Theoretical | 2 | 2010 | 785 | 0.100 |
Why?
|
| Scattering, Radiation | 2 | 2009 | 316 | 0.100 |
Why?
|
| Film Dosimetry | 1 | 2010 | 59 | 0.090 |
Why?
|
| Electronics | 1 | 2010 | 58 | 0.090 |
Why?
|
| ErbB Receptors | 1 | 2017 | 2295 | 0.080 |
Why?
|
| Body Burden | 1 | 2008 | 65 | 0.080 |
Why?
|
| Computer Simulation | 2 | 2008 | 1529 | 0.080 |
Why?
|
| Ultrasonography, Mammary | 1 | 1991 | 380 | 0.080 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2014 | 1146 | 0.080 |
Why?
|
| Lymphoma, B-Cell | 1 | 2014 | 895 | 0.080 |
Why?
|
| Exons | 2 | 2022 | 1328 | 0.080 |
Why?
|
| Photons | 1 | 2010 | 507 | 0.070 |
Why?
|
| Equipment Failure Analysis | 1 | 2007 | 329 | 0.070 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2018 | 7702 | 0.070 |
Why?
|
| Respiration | 1 | 2008 | 447 | 0.070 |
Why?
|
| Movement | 1 | 2008 | 556 | 0.060 |
Why?
|
| Reproducibility of Results | 3 | 2010 | 6009 | 0.060 |
Why?
|
| Neoplasm, Residual | 1 | 2010 | 1656 | 0.060 |
Why?
|
| Humans | 18 | 2023 | 261506 | 0.060 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2014 | 1664 | 0.060 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 5178 | 0.060 |
Why?
|
| Aged | 10 | 2022 | 70117 | 0.060 |
Why?
|
| Sensitivity and Specificity | 2 | 2009 | 4971 | 0.060 |
Why?
|
| Mutation | 2 | 2020 | 15179 | 0.060 |
Why?
|
| T-Lymphocytes | 1 | 2014 | 3869 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2017 | 10035 | 0.050 |
Why?
|
| Middle Aged | 9 | 2020 | 86204 | 0.040 |
Why?
|
| Adult | 8 | 2020 | 77950 | 0.040 |
Why?
|
| Melanoma | 1 | 2016 | 5317 | 0.040 |
Why?
|
| Edema | 1 | 2020 | 267 | 0.040 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2017 | 97 | 0.040 |
Why?
|
| Proton Therapy | 1 | 2007 | 1577 | 0.040 |
Why?
|
| Technology, Radiologic | 1 | 1997 | 80 | 0.040 |
Why?
|
| Biophysics | 1 | 1997 | 111 | 0.040 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 29902 | 0.040 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2017 | 194 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 1997 | 418 | 0.040 |
Why?
|
| Motion | 1 | 1997 | 193 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2017 | 409 | 0.030 |
Why?
|
| Endpoint Determination | 1 | 2016 | 176 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2017 | 15862 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2017 | 12873 | 0.030 |
Why?
|
| Protein Kinase C | 1 | 2017 | 396 | 0.030 |
Why?
|
| Radiotherapy, High-Energy | 1 | 1997 | 295 | 0.030 |
Why?
|
| International Cooperation | 1 | 2017 | 323 | 0.030 |
Why?
|
| Whole-Body Irradiation | 1 | 2016 | 307 | 0.030 |
Why?
|
| Metastasectomy | 1 | 2017 | 200 | 0.030 |
Why?
|
| Female | 9 | 2020 | 141928 | 0.030 |
Why?
|
| Smoking | 1 | 2023 | 2440 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2017 | 783 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2023 | 4314 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2017 | 1038 | 0.030 |
Why?
|
| Quinazolines | 1 | 2017 | 923 | 0.030 |
Why?
|
| Male | 6 | 2020 | 123000 | 0.030 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 2231 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2017 | 1987 | 0.020 |
Why?
|
| Methods | 1 | 1991 | 189 | 0.020 |
Why?
|
| Ultrasonics | 1 | 1991 | 69 | 0.020 |
Why?
|
| Spinal Cord Regeneration | 1 | 2010 | 10 | 0.020 |
Why?
|
| Pyridines | 1 | 2016 | 1244 | 0.020 |
Why?
|
| Vidarabine | 1 | 2014 | 1341 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2022 | 9244 | 0.020 |
Why?
|
| Registries | 1 | 2017 | 2170 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2017 | 3821 | 0.020 |
Why?
|
| Patient Positioning | 1 | 2010 | 195 | 0.020 |
Why?
|
| Antineoplastic Agents | 2 | 2022 | 14289 | 0.020 |
Why?
|
| In Vitro Techniques | 1 | 1991 | 1618 | 0.020 |
Why?
|
| Pyrazoles | 1 | 2016 | 1471 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2014 | 3001 | 0.020 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2018 | 2104 | 0.020 |
Why?
|
| Calibration | 1 | 2007 | 337 | 0.020 |
Why?
|
| Molecular Targeted Therapy | 1 | 2017 | 2330 | 0.020 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 5112 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2017 | 32848 | 0.020 |
Why?
|
| Transplantation Conditioning | 1 | 2014 | 2238 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2017 | 10001 | 0.020 |
Why?
|
| Survival Rate | 1 | 2017 | 12221 | 0.010 |
Why?
|
| Breast Neoplasms | 1 | 2008 | 15694 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2010 | 1648 | 0.010 |
Why?
|
| Time Factors | 1 | 2017 | 12926 | 0.010 |
Why?
|
| Software | 1 | 2010 | 1321 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2014 | 8865 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 14551 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2017 | 14889 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2018 | 7551 | 0.010 |
Why?
|
| Texas | 1 | 2011 | 6311 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2017 | 11965 | 0.010 |
Why?
|
| Retrospective Studies | 1 | 2022 | 37905 | 0.010 |
Why?
|
| Young Adult | 1 | 2017 | 21445 | 0.010 |
Why?
|
| Adolescent | 1 | 2016 | 31252 | 0.010 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2008 | 5437 | 0.010 |
Why?
|
| Neoplasms | 1 | 2018 | 15193 | 0.010 |
Why?
|
| United States | 1 | 2007 | 15433 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2008 | 7789 | 0.010 |
Why?
|